Daily Brief ECM: IPO Databook: Shenzhen Salubris Pharmaceuticals (002294 HK) – Sep 2026 and more

• A leading Chinese pharmaceutical company focused on the CKM sector, engaged in R&D, production, and sales of pharmaceuticals and medical devices. It seeks a primary HKEX listing, having been listed.
• The company ranked second in China’s in-hospital cardiovascular drug sales with 11.3% market share in 2025. Total revenue increased to RMB4,352.7 million in 2025.
• Gross profit was 3,247,584 RMB’000 and profit for the year was 652,784 RMB’000 in 2025. Total assets reached 11,297,803 RMB’000 as of December 31, 2025.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Vatai Holdings Limited is an AI-empowered global platform providing cross-border e-commerce compliance services, seeking a primary listing on HKEX. According to CIC, it was the largest provider globally and in.
• Vatai Holdings was the largest cross-border e-commerce compliance service provider globally and in China in 2025, holding 21.5% market share in China.
• Revenue was RMB528,476 and profit for the year was RMB97,175 in 2025. Net cash from operating activities was RMB269,110.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.